Glucagon-like peptide-1 was discovered as an insulinotropic peptide from the gut during a search for candidates for the incretin effect. It turned out to also inhibit glucagon secretion and is now considered an important regulator of glucose metabolism. In further investigations of its physiological effects, it also inhibited gastrointestinal secretion and motility and inhibited appetite and food intake. Because of these effects, it was eventually demonstrated to be able to improve glucose control and beta cell function in T2DM patients and was even associated with weight loss.
Radically different